WO2001091756A3 - S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders - Google Patents

S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders Download PDF

Info

Publication number
WO2001091756A3
WO2001091756A3 PCT/IB2001/000933 IB0100933W WO0191756A3 WO 2001091756 A3 WO2001091756 A3 WO 2001091756A3 IB 0100933 W IB0100933 W IB 0100933W WO 0191756 A3 WO0191756 A3 WO 0191756A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorder
disorders
anxiety
treatment
psychotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2001/000933
Other languages
French (fr)
Other versions
WO2001091756A2 (en
Inventor
Chandra Aggarwal Prakash
Teresa Annette Smolarek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26903852&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2001091756(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to UA2002119557A priority Critical patent/UA79425C2/en
Priority to AU2001258690A priority patent/AU2001258690A1/en
Priority to EP01932011A priority patent/EP1286672B1/en
Priority to HR20020953A priority patent/HRP20020953A2/en
Priority to DE60124093T priority patent/DE60124093D1/en
Priority to IL15278201A priority patent/IL152782A0/en
Priority to CA002410618A priority patent/CA2410618A1/en
Priority to PL01365576A priority patent/PL365576A1/en
Priority to HU0301747A priority patent/HUP0301747A2/en
Priority to BR0111271-6A priority patent/BR0111271A/en
Priority to JP2001587771A priority patent/JP2003534381A/en
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Priority to DK04013380T priority patent/DK1468686T3/en
Priority to SK1662-2002A priority patent/SK16622002A3/en
Priority to EEP200200670A priority patent/EE200200670A/en
Priority to EA200201168A priority patent/EA007068B1/en
Priority to MXPA02011862A priority patent/MXPA02011862A/en
Publication of WO2001091756A2 publication Critical patent/WO2001091756A2/en
Publication of WO2001091756A3 publication Critical patent/WO2001091756A3/en
Priority to IL152782A priority patent/IL152782A/en
Priority to BG107267A priority patent/BG107267A/en
Priority to IS6619A priority patent/IS6619A/en
Priority to NO20025760A priority patent/NO325077B1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

This invention relates to pharmaceutical compositions containing S-methyl-dihydro-ziprasidone and to the use of such compound and its pharmaceutically acceptable salts for the treatment of psychiatric and ocular disorders. More specifically, it relates to the use of such compound and its pharmaceutically acceptable salts for the treatment of a disorder or condition selected from: schizophrenia, anxiety disorders such as generalized anxiety disorder, panic disorder, posttraumatic stress disorder and phobias (e.g., social phobia, agoraphobia etc.); psychotic episodes of anxiety: anxiety, agitation, excessive aggression, tension, or social or emotional withdrawal associated with psychosis; psychotic mood disorders such as severe major depressive disorder; mood disorders associated with psychotic disorders such as acute mania and depression associated with bipolar disorder, and mood disorders associated with schizophrenia; behavioral disturbances associated with mental retardation, autistic disorder, and conduct disorder; dementias such as dementias associated with Alzheimer's disease; drug-induced and neurodegeneration based dyskinesias; obsessive compulsive disorder; Tourette's syndrome; glaucoma; and ischemic retinopathy.
PCT/IB2001/000933 2000-06-02 2001-05-28 S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders Ceased WO2001091756A2 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
MXPA02011862A MXPA02011862A (en) 2000-06-02 2001-05-28 S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders.
DK04013380T DK1468686T3 (en) 2000-06-02 2001-05-28 S-methyl-dihydro-ziprasidone for the treatment of psychiatric disorders
EP01932011A EP1286672B1 (en) 2000-06-02 2001-05-28 S-methyl-dihydro-ziprasidone for the treatment of ocular disorders.
HR20020953A HRP20020953A2 (en) 2000-06-02 2001-05-28 S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders
DE60124093T DE60124093D1 (en) 2000-06-02 2001-05-28 S-methyl-dihydro-ziprasidone for the treatment of eye diseases.
IL15278201A IL152782A0 (en) 2000-06-02 2001-05-28 S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders
CA002410618A CA2410618A1 (en) 2000-06-02 2001-05-28 S-methyl-dihydro-ziprasidone for treatment of psychiatric disorders
PL01365576A PL365576A1 (en) 2000-06-02 2001-05-28 S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders
HU0301747A HUP0301747A2 (en) 2000-06-02 2001-05-28 S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders
AU2001258690A AU2001258690A1 (en) 2000-06-02 2001-05-28 S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders
JP2001587771A JP2003534381A (en) 2000-06-02 2001-05-28 S-methyl-dihydro-ziprasidone for the treatment of psychiatric and eye disorders
UA2002119557A UA79425C2 (en) 2000-06-02 2001-05-28 S-methyl dihydroziprasidone for treatment of psychiatric disorders
EEP200200670A EE200200670A (en) 2000-06-02 2001-05-28 S-methyldihydroziprasidone for the treatment of psychiatric and ocular disorders
BR0111271-6A BR0111271A (en) 2000-06-02 2001-05-28 S-methyl dihydro-ziprasidone for treatment of psychiatric and eye disorders
SK1662-2002A SK16622002A3 (en) 2000-06-02 2001-05-28 S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders
EA200201168A EA007068B1 (en) 2000-06-02 2001-05-28 3-methyl-dihydro-ziprasidone for treatment of psychiatric disorders
IL152782A IL152782A (en) 2000-06-02 2002-11-11 S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders
BG107267A BG107267A (en) 2000-06-02 2002-11-12 S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders
IS6619A IS6619A (en) 2000-06-02 2002-11-14 S-methyl-dihydro-siprazidone for the treatment of psychiatric and eye disorders
NO20025760A NO325077B1 (en) 2000-06-02 2002-11-29 Use of S-methyl-dihydro-ziprasidone for the preparation of a pharmaceutical composition and a pharmaceutical composition.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US20913600P 2000-06-02 2000-06-02
US60/209,136 2000-06-02
US21217200P 2000-06-16 2000-06-16
US60/212,172 2000-06-16

Publications (2)

Publication Number Publication Date
WO2001091756A2 WO2001091756A2 (en) 2001-12-06
WO2001091756A3 true WO2001091756A3 (en) 2002-09-26

Family

ID=26903852

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/000933 Ceased WO2001091756A2 (en) 2000-06-02 2001-05-28 S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders

Country Status (44)

Country Link
US (1) US20060287336A1 (en)
EP (3) EP1286672B1 (en)
JP (2) JP2003534381A (en)
KR (1) KR20030007824A (en)
CN (1) CN1431901A (en)
AP (2) AP1831A (en)
AR (1) AR028937A1 (en)
AT (3) ATE343387T1 (en)
AU (1) AU2001258690A1 (en)
BG (1) BG107267A (en)
BR (1) BR0111271A (en)
CA (1) CA2410618A1 (en)
CY (1) CY1105992T1 (en)
CZ (1) CZ20023860A3 (en)
DE (3) DE60124791T2 (en)
DK (1) DK1468686T3 (en)
DO (1) DOP2001000181A (en)
EA (1) EA007068B1 (en)
EC (1) ECSP024369A (en)
EE (1) EE200200670A (en)
ES (1) ES2277170T3 (en)
GE (1) GEP20053512B (en)
HN (1) HN2001000119A (en)
HR (1) HRP20020953A2 (en)
HU (1) HUP0301747A2 (en)
IL (2) IL152782A0 (en)
IS (1) IS6619A (en)
MA (1) MA26908A1 (en)
MX (1) MXPA02011862A (en)
NO (1) NO325077B1 (en)
NZ (1) NZ551012A (en)
OA (1) OA12267A (en)
PA (1) PA8518301A1 (en)
PE (1) PE20011329A1 (en)
PL (1) PL365576A1 (en)
PT (2) PT1468686E (en)
SI (1) SI1468686T1 (en)
SK (1) SK16622002A3 (en)
SV (1) SV2002000473A (en)
UA (1) UA79425C2 (en)
UY (1) UY26742A1 (en)
WO (1) WO2001091756A2 (en)
YU (1) YU90702A (en)
ZA (1) ZA200209665B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7667037B2 (en) 2003-10-24 2010-02-23 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003296991A1 (en) 2002-12-13 2004-07-09 Regents Of The University Of Minnesota Scleral depressor
ES2250001B1 (en) * 2004-09-29 2007-06-01 Medichem, S.A. PROCESS FOR THE PURIFICATION OF ZIPRASIDONA.
JP2012174228A (en) * 2011-02-24 2012-09-10 Kyocera Corp Program protection device and communication apparatus
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US9981041B2 (en) * 2016-08-23 2018-05-29 Ira Jason Salzman Ophthalmic lubricating spray

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059489A2 (en) * 1999-04-06 2000-10-12 Sepracor Inc. Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW491847B (en) * 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
US6110918A (en) * 1996-05-07 2000-08-29 Pfizer Inc Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihy dro-2(1H)-indol-2-one (=ziprasidone), its preparation and its use as dopamine D2 antagonist
ATE247963T1 (en) * 1998-05-26 2003-09-15 Pfizer Prod Inc DRUG FOR TREATING GLAUCOMA AND ISCHEMIC RETINOPATHY

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059489A2 (en) * 1999-04-06 2000-10-12 Sepracor Inc. Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DANIEL D.G. ET AL: "Ziprasidone: Comprehensive overview and clinical use of a novel antipsychotic.", EXPERT OPINION ON INVESTIGATIONAL DRUGS, ( 2000 ) 9/4 (819-828)., XP001041844 *
PRAKASH C ET AL.: "Characterization of the novel benzisothiazole ring-cleaved prducts of the antipsychotic drug ziprasidone", DRUG METABOLISM AND DISPOSITION, vol. 25, no. 7, 1997, pages 897 - 901, XP001041808 *
PRAKASH C ET AL: "Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans", DRUG METABOLISM AND DISPOSITION, vol. 25, no. 7, 1997, pages 863 - 872, XP001041807 *
PRAKASH C ET AL: "Metabolism and excretion of the novel antipsychotic drug ziprasidone in rats after oral administration of a mixture of 14C- and 3H-labeled ziprasidone", DRUG METABOLISM AND DISPOSITION, vol. 25, no. 1, 1997, pages 206 - 218, XP001041804 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7667037B2 (en) 2003-10-24 2010-02-23 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone

Also Published As

Publication number Publication date
CA2410618A1 (en) 2001-12-06
HRP20020953A2 (en) 2005-02-28
DE60124093D1 (en) 2006-12-07
AP1747A (en) 2007-05-31
SK16622002A3 (en) 2004-07-07
UY26742A1 (en) 2001-12-28
DOP2001000181A (en) 2002-04-15
IL152782A0 (en) 2003-06-24
EP1698338A3 (en) 2006-09-20
NO325077B1 (en) 2008-01-28
ES2277170T3 (en) 2007-07-01
AR028937A1 (en) 2003-05-28
NZ551012A (en) 2008-04-30
OA12267A (en) 2004-01-20
EP1286672B1 (en) 2006-10-25
YU90702A (en) 2005-11-28
DK1468686T3 (en) 2007-03-12
MXPA02011862A (en) 2003-04-10
ECSP024369A (en) 2003-02-06
WO2001091756A2 (en) 2001-12-06
PE20011329A1 (en) 2002-01-15
CN1431901A (en) 2003-07-23
ATE345818T1 (en) 2006-12-15
EP1468686B1 (en) 2006-11-22
ATE343387T1 (en) 2006-11-15
GEP20053512B (en) 2005-05-10
AU2001258690A1 (en) 2001-12-11
JP2003534381A (en) 2003-11-18
CY1105992T1 (en) 2011-04-06
EP1698338B1 (en) 2008-04-09
EE200200670A (en) 2004-08-16
US20060287336A1 (en) 2006-12-21
EP1286672A2 (en) 2003-03-05
PL365576A1 (en) 2005-01-10
KR20030007824A (en) 2003-01-23
MA26908A1 (en) 2004-12-20
UA79425C2 (en) 2007-06-25
NO20025760D0 (en) 2002-11-29
DE60133596D1 (en) 2008-05-21
IL152782A (en) 2007-10-31
SV2002000473A (en) 2002-10-24
EP1698338A2 (en) 2006-09-06
HN2001000119A (en) 2001-09-11
SI1468686T1 (en) 2007-04-30
ATE391507T1 (en) 2008-04-15
EA200201168A1 (en) 2003-06-26
NO20025760L (en) 2003-01-15
EA007068B1 (en) 2006-06-30
DE60124791D1 (en) 2007-01-04
PT1698338E (en) 2008-06-03
JP2008056700A (en) 2008-03-13
DE60124791T2 (en) 2007-09-13
BG107267A (en) 2003-06-30
EP1468686A3 (en) 2004-12-01
CZ20023860A3 (en) 2004-01-14
EP1468686A2 (en) 2004-10-20
ZA200209665B (en) 2003-11-28
PA8518301A1 (en) 2002-09-17
AP1831A (en) 2008-02-26
HUP0301747A2 (en) 2003-09-29
AP2005003272A0 (en) 2005-03-31
PT1468686E (en) 2007-01-31
BR0111271A (en) 2003-06-10
IS6619A (en) 2002-11-14

Similar Documents

Publication Publication Date Title
CA2256227A1 (en) Method of treating psychiatric conditions
BR9914293A (en) Process for the purification of 1,3-propanediol
PT1586319E (en) Thiadiazolidinones as gsk-3 inhibitors
CO5611138A2 (en) ZIPRASIDONE COMPOSITION AND SYNTHETIC CONTROLS
ATE492279T1 (en) BUPROPINE METABOLITES FOR THE TREATMENT OF DEMENTIA AND OTHER CEREBROVACCULAR DISEASES
WO2006119504A3 (en) Fused heterocyclic compounds, and compositions and uses thereof
MX2007012883A (en) Dihydrobenzofuran derivatives and uses thereof.
DK1140104T3 (en) Treatment of Alzheimer's disease by increasing cytidine levels in vivo
EP2561889A3 (en) Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
WO2000002542A3 (en) Agents with an antidepressive effect containing pramipexol and an additional antidepressant drug
WO2007062999A3 (en) 1,5-substituted indol-2-yl amide derivatives
BRPI0414864A (en) multiparticulate pharmaceutical composition comprising mycophenolic acid or mycophenolate sodium and combination with rapamide
WO2001091756A3 (en) S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders
WO2003057213A3 (en) Cyclohexano- and cycloheptapyrazole derivative compounds, for use in diseases associated with the 5-ht2c receptor
ATE552251T1 (en) THIOPHENE AND FURAN COMPOUNDS
WO2008018639A3 (en) Glycine transporter inhibitor
ATE247630T1 (en) METHOD FOR PRODUCING N,N'-BIS,2,3-DIHYDROXYPROPYL)-5-((HYDROXYACETYL)METHYLAMINO) 2,4,6-TRIIODO-1,3-BENZENEDICARBOXAMIDE
EA200801302A1 (en) COMPOSITIONS AND METHODS OF TREATMENT OF CNS DISORDERS
BR0202323B1 (en) nodular cast iron alloy as well as process for plastic deformable cast iron products.
MY129575A (en) Methods, kits and compositions for using pyrrole derivatives againts anxiety
MX2008001200A (en) 2-hydroxy-propionic acid derivatives and 3-hydroxy-benzofuran-2-o ne derivatives with affinity for the gaba-b-receptor.
DE69533214D1 (en) 2,3-Dihydro-1H-isoindole derivatives, process for their preparation and their use as inhibitors of serotonin reuptake
CA2378628A1 (en) New indenoindolone derivatives, the process for preparing them and the pharmaceutical compounds that contain them
DE602005002776D1 (en) Process for the preparation of 1,3-dihydro-2H-3-benzazepin-2-one and use for the preparation of ivabradine and its pharmaceutically acceptable salts
BR9915572A (en) Process of treatment of sickle cell disease and thalassemia

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-907/02

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: DZP2002000306

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 522449

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 152782

Country of ref document: IL

Ref document number: IN/PCT/2002/01582/MU

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2001 107267

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001258690

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PV2002-3860

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 16622002

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 2410618

Country of ref document: CA

Ref document number: 2001932011

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002/09665

Country of ref document: ZA

Ref document number: 200209665

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/011862

Country of ref document: MX

Ref document number: 200201168

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 1020027016364

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 20020789

Country of ref document: UZ

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 01810620X

Country of ref document: CN

Ref document number: P20020953A

Country of ref document: HR

Ref document number: 4972

Country of ref document: GE

Ref document number: 02109196

Country of ref document: CO

Ref document number: 1200201100

Country of ref document: VN

WWP Wipo information: published in national office

Ref document number: 1020027016364

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001932011

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2002-3860

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: 1020027016364

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 2001932011

Country of ref document: EP